Holen Sie sich die Stockscreener-App
171.34
1.13%
-1.96
Vorhandelsmarkt:
172.39
1.05
+0.61%
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt AZN?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Astrazeneca Plc Aktie (AZN) Neueste Nachrichten
Judge Dismisses AstraZeneca’s Bid To Stop Maine Pharmacy Law - Bloomberg Law News
AstraZeneca's drug pipeine is splitting opinion among City analysts - Proactive Investors
ASTRAZENECA : DZ Bank gives a Buy rating - marketscreener.com
ASTRAZENECA : Gets a Buy rating from Berenberg - marketscreener.com
ASTRAZENECA : Gets a Buy rating from Goldman Sachs - marketscreener.com
ASTRAZENECA : UBS remains its Buy rating - marketscreener.com
AstraZeneca reports Phase III results for Ultomiris and Sone-Ve - Clinical Trials Arena
AstraZeneca Stock: What We Thought of Earnings - Morningstar
AstraZeneca Kept at Buy as Berenberg Notes 'Upbeat' Q2 Earnings Call - marketscreener.com
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
AZN Q2 FY2026 earnings call - finance.biggo.com
AstraZeneca PLC (AZN) Stock Forecasts - Yahoo Finance
AstraZeneca PLC (AZN) Q2 2026 Earnings Call Highlights: Strong Oncology and Rare Disease Growth ... - Yahoo Finance
AZN Q2 Earnings and Sales Beat, Key Drugs Offset Generic Pressure - TradingView
AstraZeneca’s MONTEROSA Study Tracks Real World Outcomes for STRIDE in Liver Cancer - TipRanks
AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks (NYSE:AZN) - Seeking Alpha
AstraZeneca PLC (AZN) Investigation: Bronstein, Gewirtz & Grossma - The National Law Review
AstraZeneca rallies Monday, outperforms market - MarketWatch
AstraZeneca PLC (AZN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
AstraZeneca quarterly net profit rises 2% on strong cancer drug sales - Yahoo Finance UK
Astrazeneca Rises on Profit Beat; Paramount Pauses WBD Deal | Stock Movers - marketscreener.com
AstraZeneca: In line Q2; correction of late is an entry point - marketscreener.com
Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings - Benzinga
AstraZeneca drug prices evolving in response to Trump policy, executive says - Reuters
AstraZeneca PLC Stock Analysis: Q2 Earnings Beat vs Bearish Trend - The Cryptonomist
Astrazeneca (AZN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
AstraZeneca says adjusting drug pricing over Trump policies By Investing.com - Investing.com Nigeria
Astrazeneca Q2 Earnings Call Highlights - Yahoo Finance
What's Going on With AstraZeneca Stock Monday?AstraZeneca (NYSE:AZN) - Benzinga
AstraZeneca (NASDAQ: AZN) lifts H1 profit and backs 2026 outlook - Stock Titan
AstraZeneca oncology growth continues despite product setback - Investors' Chronicle
AstraZeneca profit rises on strong cancer drug sales - Yahoo Finance
AstraZeneca Sees 2030 Goal on Track as Cancer Drugs Drive Growth - WSJ
ASTRAZENECA : Jefferies gives a Buy rating - marketscreener.com
Bronstein, Gewirtz & Grossman, LLC Encourages AstraZeneca PLC (AZN) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Mixed Ultomiris HSCT-TMA results at AstraZeneca (NASDAQ: AZN) spur paediatric filings - Stock Titan
AstraZeneca PLC 2026 Q2ResultsEarnings Call Presentation (NYSE:AZN) 2026-07-27 - Seeking Alpha
AstraZeneca to Acquire Worldwide Rights to Lung Cancer Drug for $600M - Stock Titan
AstraZeneca sales boosted by soaring demand for cancer treatments - Yahoo Finance UK
AstraZeneca (NASDAQ: AZN) Phase III Sone-Ve data show gastric survival gain - Stock Titan
ASTRAZENECA PLC ORD SHS $0.25 (AZN.L) Q2 FY2026 earnings call transcript - Yahoo Finance
AstraZeneca stock edges up on earnings beat despite revenue miss - Investing.com
AstraZeneca Q2 Core Earnings, Revenue Rise; Interim Dividend Raised - marketscreener.com
AstraZeneca PLC Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
AstraZeneca reiterates guidance after topping Q2 profit expectations; shares up - Investing.com Nigeria
AstraZeneca PLC (AZN) Stock Analysis: Exploring a 26% Potential Upside and Strong Buy Ratings - DirectorsTalk Interviews
Market Open: Vodafone raises guidance, AstraZeneca H1 growth - Yahoo Finance UK
AstraZeneca CFO says AI is not expected to lead to job cuts - marketscreener.com
AstraZeneca sales rise as demand for cancer treatments grow - Yahoo Finance UK
AstraZeneca Logs Higher First-half Profit on Strong Oncology, Rare Disease Drugs Sales; Outlook Maintained - marketscreener.com
AstraZeneca’s Cancer Medicines Spur Profit Growth - Bloomberg
AstraZeneca Q2 Pre-tax Profit Down, But EPS Rise; Backs Positive FY26 View - RTTNews
AstraZeneca Q2 Results: Adjusted EPS rises 141% YoY to $2.63 - scanx.trade
AstraZeneca reports first-half growth, disappointment in Ultomiris trial - Sharecast.com
AstraZeneca quarterly earnings top hopes amid mixed pipeline updates - marketscreener.com
Why is AstraZeneca stock climbing today? By Investing.com - Investing.com Nigeria
AstraZeneca shares climbs as full-year outlook reiterated despite recent trial failureUPDATE - Proactive financial news
AstraZeneca Q2 profit beats estimates as cancer drug sales drive growth (AZN:NYSE) - Seeking Alpha
AstraZeneca Beats Second-Quarter Earnings Forecast - Share Talk
ASTRAZENECA : Receives a Buy rating from JP Morgan - marketscreener.com
AstraZeneca PLC Declares First Interim Dividend for 2026, Payable on September 8, 2026 - marketscreener.com
AstraZeneca PLC Reconfirms Earnings Guidance for the Year 2026 - marketscreener.com
AstraZeneca PLC reports results for the quarter ended June 30Earnings Summary - TradingView
AstraZeneca reports strong first-half growth as pipeline expansion supports long-term outlook - Yahoo Finance UK
AstraZeneca PLC Reports Statistically Significant Improvement in Overall Survival with Sonesitatug Vedotin in CLDN18.2-Positive Advanced Gastric Cancers - marketscreener.com
AstraZeneca's rare disease drug misses main goal in late-stage trial - marketscreener.com
AstraZeneca’s Ultomiris misses primary endpoint in adult HSCT-TMA trial - Investing.com
AstraZeneca Posts Sales Growth on Oncology Strength - marketscreener.com
AstraZeneca’s Sone-Ve shows survival benefit in gastric cancer By Investing.com - Investing.com Nigeria
AstraZeneca’s Ultomiris misses primary endpoint in adult HSCT-TMA trial By Investing.com - Investing.com Canada
0.25%
0.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):